Clinical Trials for Liver Cancer
230 liver cancer trials indexed, 115 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Liver Cancer
Liver cancer occurs when abnormal cells grow uncontrollably in the liver, forming tumors. The most common type is hepatocellular carcinoma, which begins in the main liver cells called hepatocytes. Liver cancer often develops due to chronic liver damage caused by inflammation or scarring. Doctors diagnose liver cancer through imaging tests such as ultrasound, CT scans, or MRI. Blood tests measuring alpha-fetoprotein (AFP) levels can also help detect liver cancer. A biopsy may be performed to confirm the diagnosis and determine the cancer’s characteristics.
Symptoms of liver cancer may include abdominal pain, unexplained weight loss, loss of appetite, jaundice (yellowing of the skin and eyes), and swelling in the abdomen. These symptoms often appear only after the disease has advanced. Liver cancer typically affects adults over 50 years old, but it can develop earlier in people with risk factors. The highest risk is among those with chronic hepatitis B or C infections, cirrhosis from alcohol use or fatty liver disease, and exposure to aflatoxins, which are toxins produced by certain molds. Men are also more likely to develop liver cancer than women.
Liver cancer is a serious medical and social issue worldwide. It ranks as the sixth most common cancer and the third leading cause of cancer-related deaths globally. In the United States, liver cancer accounts for about 2.4% of all new cancer cases but causes a disproportionate number of deaths due to its aggressive nature. The five-year survival rate remains below 20%, highlighting the need for improved detection and treatment. The economic burden is also significant, with high costs related to hospital care, medications, and lost productivity. Understanding liver cancer’s impact helps guide research and healthcare priorities.
The Liver Cancer Treatment Landscape
The first-line treatment for liver cancer depends on the stage of the disease and liver function. Early-stage liver cancer may be treated with surgery to remove the tumor or liver transplantation. Localized treatments like radiofrequency ablation or transarterial chemoembolization (TACE) are options when surgery is not possible. For advanced liver cancer, systemic therapies become the main approach. The goal is to control tumor growth and extend survival while maintaining quality of life. Treatment plans often follow a tiered approach, starting with the most effective and least toxic options first.
When first-line treatments fail or the cancer progresses, second- and third-line therapies are considered. These include targeted therapies and immunotherapies. Targeted drugs work by interfering with specific molecules that promote cancer growth. Examples include tyrosine kinase inhibitors such as sorafenib and lenvatinib. Immunotherapy drugs, like checkpoint inhibitors, help the immune system recognize and attack cancer cells. These options provide additional hope but may not work for everyone. Researchers continue to explore combinations and new agents to improve outcomes in later treatment stages.
Despite advances, current treatments have limitations. Some patients do not respond well to available drugs, especially those with poor liver function or aggressive tumor biology. Resistance to therapy often develops, making cancer harder to control. Side effects from systemic drugs can reduce quality of life and lead to treatment discontinuation. Research is focusing on identifying biomarkers to predict who will benefit most from certain treatments and developing therapies with fewer side effects. Clinical trials play a key role in testing new approaches to address these gaps.
Why Clinical Trials Matter for Liver Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. They provide closer medical monitoring and support during the study period. Participating in a trial also contributes to scientific knowledge that may help future patients. According to ClinicalTrials.gov, there are currently 230 liver cancer clinical trials registered, with 115 actively recruiting participants. This large number reflects ongoing efforts to find better ways to detect, treat, and manage liver cancer. Trials cover a range of interventions, including drugs, devices, and behavioral strategies.
Joining a clinical trial involves certain risks. The effectiveness of the new treatment is not guaranteed, and some patients may receive a placebo or standard care instead. Additional clinic visits and tests are often required, which can be time-consuming. Side effects from experimental treatments may be unknown or more severe than standard therapies. It is important for patients to discuss these factors with their healthcare team and understand the trial’s purpose and procedures before enrolling.
Clinical trials for liver cancer are sponsored by a variety of organizations. Academic institutions conduct many studies to explore novel scientific ideas. Pharmaceutical companies develop and test new drugs through industry-sponsored trials. Cooperative groups, which are networks of researchers and hospitals, also run trials to gather data from multiple centers. ClinicalTrials.gov serves as a comprehensive registry where patients and doctors can find detailed information about available trials. This transparency helps match patients with studies that fit their needs and supports ethical research practices.
What to Look for in a Liver Cancer Clinical Trial
Clinical trials are divided into phases that help researchers test new treatments safely and effectively. Phase 1 trials focus on safety and dosage, involving a small number of participants. Phase 2 trials look at how well the treatment works and continue to assess safety. Phase 3 trials compare the new treatment with the current standard treatments in larger groups. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For liver cancer, most trials are in Phase 2 with 70 studies, followed by 63 in Phase 1, 33 with no phase specified, and 15 in Phase 3.
When joining a liver cancer trial, there are specific inclusion criteria that participants must meet. These often include certain age ranges, such as adults over 18 years old. Prior treatments can affect eligibility; some trials require patients who have not had previous therapy, while others accept those who have tried certain drugs or surgeries. Biomarkers, which are biological signs of the cancer, may also be used to select patients. Staging of liver cancer, which describes how advanced the disease is, is another key factor. Additionally, the length of time since diagnosis or disease progression may be considered.
Exclusion criteria are also important and help protect patient safety. People with other serious health conditions, like heart or kidney problems, may be excluded to avoid complications. Potential drug interactions can be a concern if a participant is taking medications that might interfere with the trial treatment. Safety thresholds, such as liver function tests or blood counts, are used to decide if a person can safely join. These criteria help ensure that the trial results are reliable and that participants are not put at unnecessary risk.
From a patient’s perspective, practical details should be considered before enrolling. Trial duration varies and can last from a few months to several years. The visit schedule may require frequent trips to the clinic for tests and treatment, which can affect daily life. Travel to the study site might be needed, so distance and transportation options are important. When talking with the research team, patients should ask: How long will the trial last? What side effects might occur? How often will I need to visit the clinic? What happens if I decide to leave the trial early?
Primary Sources and Further Reading
For patients and caregivers seeking more information about liver cancer and clinical trials, trusted sources offer detailed and up-to-date guidance. These resources provide explanations about the disease, treatment options, and how clinical trials work. They also include tools to find ongoing studies and support services.
- National Cancer Institute: Liver Cancer
- MedlinePlus: Liver Cancer
- ClinicalTrials.gov: Liver Cancer Trials
- Centers for Disease Control and Prevention: Liver Cancer
Latest Research and Emerging Treatments for Liver Cancer (2026)
Recent liver cancer research is focusing on immunotherapy and targeted drugs to improve treatment options for patients. Trials are testing combinations like nivolumab and ipilimumab, two immune checkpoint inhibitors that help the immune system recognize and attack cancer cells. This approach is being studied as a first-line liver cancer treatment to see if it can extend survival compared to standard drugs such as sorafenib and lenvatinib, which work by blocking signals that promote cancer growth (NCT04039607).
Another area of study involves combining immunotherapy with radiation. The HELIO-RT trial is testing whether adding stereotactic body radiation therapy to immune drugs like atezolizumab and durvalumab can better control advanced liver cancer. Radiation targets tumors precisely, which may help the immune system respond more effectively. This could offer a new treatment option that might help patients live longer by enhancing the effects of immune-based drugs (NCT07166406).
For patients with resectable liver cancer at high risk of recurrence, new drugs like tislelizumab combined with lenvatinib are being studied before surgery. Tislelizumab is an immune checkpoint inhibitor, and lenvatinib blocks blood vessel growth in tumors. Early data suggests this combination might reduce the chance of cancer coming back after surgery (NCT07475026). Other trials are comparing types of radiation therapy, such as proton versus photon therapy, to find safer options that protect healthy tissue while treating liver cancer (NCT03186898). These studies reflect ongoing efforts to expand liver cancer new treatment 2026 options, aiming to improve patient outcomes and quality of life.
Frequently asked questions about Liver Cancer trials
How do I find Liver Cancer clinical trials?
The authoritative source for Liver Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 230 liver cancer studies are currently indexed. You can search by entering "liver cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new liver cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Liver Cancer trials in?
Across the 230 liver cancer trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Liver Cancer clinical trials are currently recruiting?
As of the latest scan, 115 liver cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 230 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting liver cancer trial matches their tracked condition.
Stay informed about liver cancer research
Get a weekly briefing with the trials that matter most.